OQROGet OQRO Pro
Insider trade

Boston Scientific (BSX)CEO sold ~$16.4M

Michael F Mahoney, CEO at Boston Scientific, sold ~$16.4M of Boston Scientific shares.

~$16.4M
Approx. value · 164K sh @ $100.01
1.59M
Holds after · shares reported
Traded
Apr 1, 2025
Filed
Apr 2, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 3, 2024InsiderOfficer purchased ~$4.5K of BSX shares in the open market
  2. Dec 10, 2024InsiderOfficer sold ~$1.8K of BSX shares in the open market
  3. Feb 3, 2025Insider · 1 personInsiders: 2 sales (~$1.8M)
  4. Feb 7, 2025InsiderOfficer sold ~$685K of BSX shares in the open market
  5. Feb 11, 2025InsiderDirector sold ~$1.27M of BSX shares in the open market
  6. Feb 12, 2025Insider · 3 peopleInsiders: 3 sales (~$3.6M)
  7. Feb 13, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  8. Feb 14, 2025InsiderOfficer sold ~$128K of BSX shares in the open market
  9. Feb 18, 2025Insider · 2 peopleInsiders: 3 sales (~$2.1M)
  10. Feb 19, 2025Insider · 3 peopleInsiders: 3 sales (~$7.6M)
  11. Feb 21, 2025InsiderOfficer sold ~$505K of BSX shares in the open market
  12. Feb 24, 2025Insider · 2 peopleInsiders: 2 sales (~$1.9M)
  13. Feb 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  14. Feb 25, 2025InsiderOfficer sold ~$280K of BSX shares in the open market
  15. Feb 28, 2025InsiderOfficer sold ~$1M of BSX shares in the open market
  16. Mar 3, 2025InsiderOfficer sold ~$750K of BSX shares in the open market
  17. Mar 3, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  18. Mar 4, 2025InsiderOfficer sold ~$50K of BSX shares in the open market
  19. Mar 17, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  20. Mar 21, 2025InsiderOfficer sold ~$487K of BSX shares in the open market
  21. Apr 1, 2025 · this disclosureInsiderCEO sold ~$16.4M of BSX shares in the open market

What came next

  1. Apr 21, 2025InsiderOfficer sold ~$459K of BSX shares in the open market
  2. Apr 21, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
  3. Apr 28, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  4. May 1, 2025Insider · 2 peopleInsiders: 3 sales (~$18.6M)
  5. May 5, 2025InsiderOfficer sold ~$478K of BSX shares in the open market
  6. May 12, 2025CongressDisclosed sale of BSX — reported range $15,001 - $50,000
  7. May 13, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  8. May 21, 2025InsiderOfficer sold ~$514K of BSX shares in the open market
  9. May 29, 2025InsiderDirector sold ~$418K of BSX shares in the open market
  10. Jun 2, 2025Insider · 1 personInsiders: 2 sales (~$17.1M)
  11. Jun 4, 2025InsiderOfficer sold ~$5.8M of BSX shares in the open market
  12. Jun 11, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  13. Jun 26, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  14. Jul 1, 2025InsiderOfficer sold ~$5.35M of BSX shares in the open market
  15. Jul 9, 2025FDAFDA device clearance: Flexiva Pulse Laser Fiber; Flexiva Pulse TracTip Laser Fiber; Flexiva Pulse ID Laser Fiber; Flexiva Pulse ID TracTip Laser Fibers
  16. Jul 24, 2025FDARecall: ENDOTAK RELIANCE G/SG with 4-SITE Connector, transvenous defibrillation lead, Permanent Defibrillator Electrodes; Model Nos. 0282, 0283, 0285, 0286, 0292, 0293…
  17. Jul 24, 2025FDARecall: RELIANCE 4-FRONT, endocardial cardioversion/defibrillation and pace/sense lead, Permanent Defibrillator Electrodes; Model Nos. 0654, 0655, 0657, 0658, 0682, 06…
  18. Jul 24, 2025FDARecall: ENDOTAK RELIANCE G/SG, transvenous defibrillation lead, implantable cardioverter defibrillator (non-CRT); Model Nos. 0160, 0161, 0162, 0163, 0164, 0165, 0166,…
  19. Jul 25, 2025InsiderDirector sold ~$424K of BSX shares in the open market
  20. Jul 29, 2025FDARecall: WATCHMAN TruSeal Access System SGL, US, Material Number (UPN) M635TU70010; intended to provide vascular and transseptal access for all WATCHMAN Left Atrial App…
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

Other recent filings by Michael F Mahoney, Chairman, President & CEO

The full history of Michael F Mahoney, Chairman, President & CEO is on the profile page.

How this filing works

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data